Pregnancy after breast cancer:
Why we need the Baby Time study
70% of women with breast cancer are recommended hormone therapy for up to 10 years following active treatment. For these women, the very same treatments that reduce the risk of a recurrence are contraindicated with pregnancy. This means a young woman who is diagnosed at age 30 could be 40 by the time she can safely try to start having a family.
Rethink Breast Cancer is asking you to help fund the international Baby Time (POSITIVE) clinical trial in Canada to provide answers for future generations of young women who wish to interrupt their endocrine therapy to try to have a baby and evaluate the safety of doing so.
WHERE THE MONEY GOES
More than 60 breast cancer centres in 20 countries around the world are participating in the Baby Time study. Rethink Breast Cancer has committed to raising $100,000+ over the next 4 years to run the Canadian research arm of this study. But we can’t do it without your help!
We need to raise $100,000 over four years so that breast cancer centres across Canada can begin enrolling and studying patients. Money raised beyond this will be used to enroll additional women ongoing over the next four years.
It costs approximately $3,000 for each woman to participate in the trial.
This includes all start up costs to get the study up and running with Health Canada and the Research Ethics Board as well as:
- recruitment and enrollment
- nursing staff costs
- data collection, analysis and reporting
- personalized care by dedicated medical team
- coordination of data with all participating centres
- follow up of each participant for up to 10 years*
- providing the Canadian data to the international centre
*Each woman will be guided through taking a break from their endocrine therapy (3 months), attempting pregnancy (up to 2 years) and then monitored (up to 10 years) to track possible recurrence of breast cancer.
How to participate
If you would like to participate in the Baby Time study in Canada please speak with your oncologist.
The criteria to participate is pre-menopausal women with:
- Hormone-sensitive early breast cancer
- Endocrine therapy for 18 to 30 months
- 42 years of age or younger at enrolment
- Wish to interrupt endocrine therapy to attempt pregnancy
The first two trial sites opened in Canada in October 2016 with more to be confirmed over the coming months!
Sunnybrooke Odette Cancer Centre in Toronto, Ontario
- Qualified Investigator: Dr. Ellen Warner
- Primary Clinical Research Associate: Ms. Debra Burns
Centre hospitalier universitaire de Sherbrooke in Sherbrooke, Quebec
- Qualified Investigator: Dr. Michel Pavic
- PCRA: Ms. Anick Champoux
Mount Sinai Hospital in Toronto, Ontario
- Qualified Investigator: Dr. Christine Elser
- PCRA: Ms. Billie Lu
Tom Baker Cancer Centre in Calgary, Alberta
- Qualified Investigator: Dr. Marc Webster
- PCRA: Ms. Marny Yar
If you fit the criteria and live within an accessible distance to one of the trial sites please contact email@example.com to be connected.
The Canadian Cancer Trials Group (CCTG) is a cancer clinical trials cooperative group that conducts phase I-III trials testing anti-cancer and supportive therapies across Canada and internationally. The CCTG’s Central Office is located at Queen’s University in Kingston, Ontario, Canada.